MA58208B1 - Acides nucléiques pour inhiber l'expression de lpa dans une cellule - Google Patents

Acides nucléiques pour inhiber l'expression de lpa dans une cellule

Info

Publication number
MA58208B1
MA58208B1 MA58208A MA58208A MA58208B1 MA 58208 B1 MA58208 B1 MA 58208B1 MA 58208 A MA58208 A MA 58208A MA 58208 A MA58208 A MA 58208A MA 58208 B1 MA58208 B1 MA 58208B1
Authority
MA
Morocco
Prior art keywords
expression
lpa
inhibiting
cell
nucleic acids
Prior art date
Application number
MA58208A
Other languages
English (en)
Inventor
Lucas Bethge
Judith Hauptmann
Christian Frauendorf
David Anthony Rider
Adrien Weingaertner
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/081106 external-priority patent/WO2019092283A1/fr
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of MA58208B1 publication Critical patent/MA58208B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des produits et des compositions ainsi que leurs utilisations. En particulier, l'invention concerne des produits d'acide nucléique qui interfèrent avec l'expression du gène lpa ou inhibent son expression, de préférence pour une utilisation en tant que traitement, prévention ou réduction du risque de souffrir d'une maladie cardiovasculaire telle qu'une coronaropathie, une sténose aortique ou un accident vasculaire cérébral, ou tout autre trouble, pathologie ou syndrome lié à des taux élevés de particules de lp(a).
MA58208A 2018-11-13 2019-11-13 Acides nucléiques pour inhiber l'expression de lpa dans une cellule MA58208B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2018/081106 WO2019092283A1 (fr) 2017-11-13 2018-11-13 Acides nucléiques permettant d'inhiber l'expression de lpa dans une cellule
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (fr) 2018-11-13 2019-11-13 Acides nucléiques permettant d'inhiber l'expression de lpa dans une cellule

Publications (1)

Publication Number Publication Date
MA58208B1 true MA58208B1 (fr) 2022-12-30

Family

ID=66554180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58208A MA58208B1 (fr) 2018-11-13 2019-11-13 Acides nucléiques pour inhiber l'expression de lpa dans une cellule

Country Status (29)

Country Link
US (2) US20220002722A1 (fr)
EP (2) EP4219712A3 (fr)
JP (1) JP7245328B2 (fr)
KR (1) KR102553386B1 (fr)
CN (1) CN113227372A (fr)
AU (1) AU2019380628A1 (fr)
BR (1) BR112021009213A2 (fr)
CA (1) CA3119239A1 (fr)
CL (1) CL2021001225A1 (fr)
CO (1) CO2021007372A2 (fr)
CR (1) CR20210301A (fr)
DK (1) DK3880818T3 (fr)
EA (1) EA202190895A1 (fr)
ES (1) ES2932295T3 (fr)
FI (1) FI3880818T3 (fr)
HR (1) HRP20221358T1 (fr)
HU (1) HUE060703T2 (fr)
IL (1) IL283159A (fr)
LT (1) LT3880818T (fr)
MA (1) MA58208B1 (fr)
MX (1) MX2021005590A (fr)
PE (1) PE20211282A1 (fr)
PH (1) PH12021550801A1 (fr)
PL (1) PL3880818T3 (fr)
PT (1) PT3880818T (fr)
RS (1) RS63778B1 (fr)
SG (1) SG11202103882QA (fr)
SI (1) SI3880818T1 (fr)
WO (1) WO2020099476A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520531A (zh) * 2017-04-05 2019-11-29 赛伦斯治疗有限责任公司 产品和组合物
EP4219716A3 (fr) 2017-11-13 2024-03-27 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression de lpa dans une cellule
DK3880818T3 (da) 2018-11-13 2022-12-05 Silence Therapeutics Gmbh Nukleinsyrer til inhibering af ekspression af LPA i en celle
JP2023545502A (ja) 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
WO2023041508A2 (fr) * 2021-09-14 2023-03-23 Argonaute RNA Limited Traitement d'une maladie cardiovasculaire
WO2023152194A1 (fr) 2022-02-09 2023-08-17 Silence Therapeutics Gmbh Inhibition thérapeutique de l'expression de lpa
CN114703184A (zh) * 2022-03-11 2022-07-05 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024013334A1 (fr) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Acides nucléiques pour inhiber l'expression de l'agt dans une cellule
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US20060160759A1 (en) 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
WO2016149020A1 (fr) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Agents d'interférence arn
JOP20210043A1 (ar) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3228326A1 (fr) * 2016-04-05 2017-10-11 Silence Therapeutics GmbH Acide nucléique lié à un glycoconjugué trivalent
CN110520531A (zh) 2017-04-05 2019-11-29 赛伦斯治疗有限责任公司 产品和组合物
EP3735461A1 (fr) * 2017-11-13 2020-11-11 Silence Therapeutics GmbH Acides nucléiques permettant d'inhiber l'expression de l'aldh2 dans une céllule
EP4219716A3 (fr) * 2017-11-13 2024-03-27 Silence Therapeutics GmbH Acides nucléiques pour inhiber l'expression de lpa dans une cellule
DK3880818T3 (da) 2018-11-13 2022-12-05 Silence Therapeutics Gmbh Nukleinsyrer til inhibering af ekspression af LPA i en celle

Also Published As

Publication number Publication date
KR102553386B1 (ko) 2023-07-07
PT3880818T (pt) 2022-12-06
CR20210301A (es) 2021-09-16
CN113227372A (zh) 2021-08-06
WO2020099476A1 (fr) 2020-05-22
DK3880818T3 (da) 2022-12-05
US20220002722A1 (en) 2022-01-06
EP3880818A1 (fr) 2021-09-22
EA202190895A1 (ru) 2021-08-10
CO2021007372A2 (es) 2021-07-09
SG11202103882QA (en) 2021-05-28
ES2932295T3 (es) 2023-01-17
PL3880818T3 (pl) 2023-01-23
HRP20221358T1 (hr) 2022-12-23
MX2021005590A (es) 2023-01-24
BR112021009213A2 (pt) 2021-08-10
KR20210095878A (ko) 2021-08-03
FI3880818T3 (fi) 2022-12-15
US20220170016A1 (en) 2022-06-02
EP4219712A2 (fr) 2023-08-02
LT3880818T (lt) 2022-12-27
SI3880818T1 (sl) 2023-01-31
CL2021001225A1 (es) 2021-12-24
US11499153B2 (en) 2022-11-15
IL283159A (en) 2021-06-30
AU2019380628A1 (en) 2021-05-20
EP3880818B1 (fr) 2022-09-28
JP2022507282A (ja) 2022-01-18
PH12021550801A1 (en) 2021-10-04
RS63778B1 (sr) 2022-12-30
CA3119239A1 (fr) 2020-05-22
JP7245328B2 (ja) 2023-03-23
HUE060703T2 (hu) 2023-04-28
EP4219712A3 (fr) 2023-11-22
PE20211282A1 (es) 2021-07-19

Similar Documents

Publication Publication Date Title
MA58208B1 (fr) Acides nucléiques pour inhiber l'expression de lpa dans une cellule
MA52488B1 (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
MA41135B1 (fr) Benzamides substitués 1,3-thiazol-2-yl
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MX2020009812A (es) COMPOSICIONES DE ARNI DE 17ß-HIDROXIESTEROIDE DESHIDROGENASA TIPO 13 (HSD17B13) Y MÉTODOS DE USO DE LAS MISMAS.
MA34516B1 (fr) Imidizopyridazines substituees
TN2019000126A1 (fr) Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MA42701B1 (fr) Compositions d'insuline à action rapide
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA33299B1 (fr) Nouvelle formulation de naproxène
MA30762B1 (fr) Anticorps specifiques du prlr et leurs utilisations
MA30260B1 (fr) Acides 4-phenyl-thiazole-5-carboxyliques et amides d'acide 4-phenyl-thiazole-5-carboxylique en tant qu'inhibiteurs de plk 1
MA46611B1 (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
FR3065371B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
MA39407A1 (fr) Compositions de cyclodextrine et de dérivés de budésonide et procédés associés
FR3070263B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite
MA40703A1 (fr) Procédé de préparation de diosmine
MA53521A1 (fr) Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
MD3880818T2 (ro) Acizi nucleici pentru inhibarea expresei LPA într-o celulă
MA53285B1 (fr) Inhibiteurs de transglutaminase 2 (tg2)
FR3073737B1 (fr) La methode de traitement de la rhinosinusite
FR3071496B1 (fr) Glyceride mixte d'acide formique, composition comprenant au moins un tel glyceride mixte, procede de preparation et utilisations
MA38655A1 (fr) Nouveaux composés destinés au traitement du cancer